CurrentCignaPolicy N/A

Tocilizumab (Actemra/Avtozma/Tyenne) prior authorization

This document is a Cigna prior authorization/coverage review form for intravenous and subcutaneous tocilizumab products (Actemra, Avtozma, Tyenne) describing required information and condition-specific questions to determine medical necessity for various indications.

Policy Summary

PayerCigna

PolicyTocilizumab (Actemra/Avtozma/Tyenne) prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a completed prior authorization form including patient/prescriber identifiers, medication details, indication, J-code, and required indication-specific questionnaire responses.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~20document chunks/pages

Multipleindications listed

6 monthsresponse assessment interval

3 monthsRA DMARD trial

Condition-Specific Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Indication selection: Request must include one selected indication from the form list (eg Castleman disease; COVID-19; Crohn's disease; CRS related to CAR T or bispecifics; GCA; GVHD; PMR; RA; Still's disease/SJIA; VEXAS; other).

See chunk 7

Rheumatoid Arthritis - new start or <6 months: For RA new starts or patients currently receiving <6 months of tocilizumab: trial of ≥1 conventional synthetic DMARD for ≥3 months AND trial of ≥1 biologic for ≥3 months AND medication prescribed by or in consultation with a rheumatologist.DMARD ≥3 months; biologic ≥3 months

Chunks 8-9

Rheumatoid Arthritis - continuation ≥6 months: For RA patients on tocilizumab ≥6 months: documentation of beneficial clinical response from baseline when assessed by at least one objective measure (eg CDAI, DAS28-ESR/CRP, PAS-II, RAPID-3, SDAI) AND improvement in at least one symptom (eg decreased joint pain, morning stiffness, fatigue, improved function).>=6 months therapy

Chunk 9

Castleman disease - new start or <6 months: For Castleman disease new starts or <6 months: indicate unicentric vs multicentric disease, document HIV/HHV-8 status if unicentric, and medication prescribed by or in consultation with an oncologist or hematologist.

Chunks 10-11

Castleman disease - continuation ≥6 months: For Castleman disease patients on tocilizumab ≥6 months: documentation of beneficial clinical response from baseline by at least one objective measure (eg improvement/normalization of CRP, ESR, fibrinogen, albumin, hemoglobin; increased BMI; reduction in lymphadenopathy) AND improvement in at least one symptom (eg reduced fatigue, improved physical function).>=6 months therapy

Chunk 11

Giant Cell Arteritis - new start or <6 months: For GCA new starts or <6 months: document trial of systemic corticosteroid or contraindication and medication prescribed by or in consultation with a rheumatologist.

Chunks 15-16 (GCA items referenced in form set)

Giant Cell Arteritis - continuation ≥6 months: For GCA patients on tocilizumab ≥6 months: documentation of beneficial clinical response from baseline by at least one objective measure (eg CRP, ESR, resolution of fever, steroid dose reduction) AND improvement in at least one symptom.>=6 months therapy

Chunk 16

Polymyalgia Rheumatica - new start or <6 months: For PMR new starts or <6 months: trial of one systemic corticosteroid is requested and medication should be prescribed by or in consultation with a rheumatologist.

Chunks 15-16

Polymyalgia Rheumatica - continuation ≥6 months: For PMR patients on therapy ≥6 months: documentation of beneficial clinical response from baseline by at least one objective measure (eg CRP, ESR, fever resolution, steroid dose reduction) AND improvement in at least one symptom (eg decreased shoulder/hip pain, improved range of motion).>=6 months therapy

Chunk 16

Still's disease and SJIA - new start or <6 months: For adult Still's disease or SJIA new starts or <6 months: indicate concomitant therapies and ensure medication is prescribed by or in consultation with a rheumatologist.

Chunks 17-20

Still's disease and SJIA - continuation ≥6 months: For Still's disease/SJIA patients on tocilizumab ≥6 months: documentation of beneficial clinical response from baseline when assessed by at least one objective measure (eg resolution of fever, improvement in rash, normalization of CRP/ESR, reduced corticosteroid dose) AND improvement in at least one symptom (eg less joint pain, decreased fatigue, improved function).>=6 months therapy

Chunks 17-20

Concomitant therapy (applies to many indications): Form asks whether tocilizumab will be given alone or in combination with a biologic, targeted synthetic oral small molecule, or conventional synthetic DMARD; select appropriate option.choice

See repeated combination-therapy lists in chunks 8,10,13,15,17,19,21,24,26,29,31

Polyarticular JIA - prior therapy and prescribing: For pJIA new starts or <6 months: has the patient tried one other systemic therapy (eg MTX, sulfasalazine, leflunomide, NSAID, or a biologic)? If starting IV tocilizumab, will patient concurrently start MTX, sulfasalazine, or leflunomide? Is there an absolute contraindication to conventional DMARDs? Is medication prescribed by or in consultation with a rheumatologist?

Chunks 21-23

Polyarticular JIA - continuation ≥6 months: For pJIA patients on tocilizumab ≥6 months: documentation of beneficial clinical response from baseline by at least one objective measure (eg JDAS, cJDAS, JSpADA, serum markers, reduced corticosteroid dose) AND improvement in at least one symptom (eg improved motion, less pain, decreased morning stiffness).>=6 months therapy

Chunk 23

Cytokine Release Syndrome (CRS) - CAR T or bispecifics: For CRS related to CAR T-cell therapy or bispecific antibodies: indicate exposure to CAR T or bispecific agent and concomitant therapy; for immunotherapy-related toxicity document if toxicity occurred while receiving a checkpoint inhibitor; for new starts or <6 months document symptomatic status despite trial of at least one systemic corticosteroid; medication should be prescribed by or in consultation with appropriate specialist (eg rheumatologist, hepatologist, gastroenterologist, pulmonologist, or oncologist).

Chunks 24-28

CRS - continuation ≥6 months: For CRS patients on tocilizumab ≥6 months: documentation of beneficial clinical response from baseline when assessed by at least one objective measure dependent on organ involvement (eg normalization of CRP/ESR or LFTs) AND improvement in at least one relevant symptom.>=6 months therapy

Chunk 28

Graft-versus-host disease (GVHD) - prior therapy and duration: For GVHD new starts or patients receiving <1 month IV tocilizumab: has the patient tried at least one systemic medication for GVHD (examples listed)? Is the medication prescribed by or in consultation with an oncologist, hematologist, or transplant-affiliated physician? For patients already receiving IV tocilizumab, confirm at least 1 month of therapy to assess response.Minimum IV duration: >=1 month for response assessment

Chunks 29-30

GVHD - ongoing response: For GVHD patients on therapy ≥1 month: documentation of beneficial clinical response from baseline by at least one objective measure (eg normalization of LFTs, RBC or platelet counts, resolution of fever or rash) AND improvement in at least one symptom (eg skin, oral, ocular, GI manifestations).>=1 month therapy

Chunk 30

VEXAS syndrome - diagnostic confirmation and corticosteroid trial: For VEXAS new starts or patients receiving <6 months of tocilizumab: documentation of a molecular genetic test demonstrating a pathogenic or likely pathogenic UBA1 gene variant AND documentation of trial of systemic corticosteroid therapy or documentation that systemic corticosteroids are contraindicated; medication should be prescribed by or in consultation with an appropriate specialist (rheumatologist, hematologist, dermatologist, immunologist, or autoinflammatory specialist).Genetic confirmation required for new starts; corticosteroid trial documented

Chunks 31-32

VEXAS - continuation ≥6 months: For VEXAS patients on tocilizumab ≥6 months: documentation of beneficial clinical response from baseline when assessed by at least one objective measure (eg resolution of fever, improvement in skin, normalization of CRP/ESR, reduced corticosteroid dose) AND improvement in at least one symptom (eg decreased cough/dyspnea, improved ocular symptoms, improved function).>=6 months therapy

Chunk 32

Polyarticular juvenile idiopathic arthritis

Polyarticular juvenile idiopathic arthritis — coverage questions

Concomitant therapy: Will the medication be given with a biologic, targeted synthetic, conventional DMARD, or no combination?choice

Biologics and targeted synthetic examples listed (chunk 21)

Prior systemic therapy for new starts: For new starts or patients receiving <6 months: has the patient tried one other systemic therapy for this condition (eg methotrexate, sulfasalazine, leflunomide, NSAID, or a biologic DMARD)?boolean

Yes required unless contraindication or aggressive disease (chunk 22)

Concurrent MTX for IV tocilizumab: If initiating IV tocilizumab, will the patient be starting concurrently on methotrexate, sulfasalazine, or leflunomide?boolean

Chunk 22

Contraindication to conventional DMARDs: Does the patient have an absolute contraindication to MTX, sulfasalazine, or leflunomide? (examples provided on form)boolean

Chunk 22

Prescriber specialty: Is the medication prescribed by or in consultation with a rheumatologist? (required for new starts or <6 months)boolean

Chunk 22

Ongoing response ≥6 months: When assessed by at least one objective measure, has the patient experienced a beneficial clinical response from baseline? (Examples include JDAS, cJDAS, JSpADA, serum markers, reduced corticosteroid dose) AND improvement in at least one symptom (eg improved motion, less pain, decreased morning stiffness).boolean

Chunk 23

Cytokine release syndrome (CRS)

Cytokine release syndrome (CRS) associated with CAR T-cell therapy or bispecific antibodies — coverage questions

Concomitant therapy: Will the requested medication be given with a biologic, targeted synthetic oral small molecule, conventional DMARD, or no combination?choice

Lists of agents provided in form (chunks 24,26,27)

CART/bispecific exposure: Is the medication being prescribed for a patient who has been or will be treated with CAR T-cell therapy or a bispecific antibody?boolean

Examples of CAR T and bispecific therapies listed (chunks 25, 26)

Immunotherapy-related toxicity: For CRS related to immunotherapy: has the patient developed an immunotherapy-related toxicity and did it occur while receiving a checkpoint inhibitor?boolean

Yes/No branching per form (chunks 27,28)

Corticosteroid trial: For new starts or patients receiving <6 months: is the patient symptomatic despite a trial of at least ONE systemic corticosteroid (eg methylprednisolone, prednisone)?boolean

Chunk 28

Prescriber specialty: Is the medication prescribed by or in consultation with an appropriate specialist (eg rheumatologist, hepatologist, gastroenterologist, pulmonologist, or oncologist)?boolean

Required for new starts or <6 months (chunk 28)

Ongoing response ≥6 months: For patients on therapy ≥6 months: when assessed by at least one objective measure, has the patient experienced a beneficial clinical response from baseline (examples dependent on organ involvement such as normalization of CRP/ESR or LFTs) AND improvement in at least one relevant symptom?boolean

Chunk 28

Graft-versus-host disease (GVHD)

Graft-versus-host disease — coverage questions

Concomitant therapy: Will the requested medication be given in combination with a biologic, targeted synthetic oral small molecule, conventional DMARD, or no combination?choice

List provided on form (chunk 29)

Current tocilizumab use: Is the patient currently receiving a tocilizumab intravenous product?boolean

Chunk 29

Minimum IV duration: Has the patient already received at least 1 month of IV tocilizumab therapy? (Answer No if <1 month or restarting therapy)boolean

Minimum duration for response assessment (chunks 29-30)

Prior systemic medication trial for new starts: For new starts or patients receiving <1 month: has the patient tried at least one systemic medication for GVHD (examples listed, eg corticosteroids, antithymocyte globulin, cyclosporine, tacrolimus, ruxolitinib)?boolean

Chunk 30

Prescriber specialty: Is the requested medication prescribed by or in consultation with an oncologist, hematologist, or a physician affiliated with a transplant center?boolean

Required for new starts or <1 month (chunk 30)

Ongoing response ≥1 month: When assessed by at least one objective measure, has the patient experienced a beneficial clinical response from baseline? (Examples: normalization of LFTs, red blood cell or platelet count, resolution of fever or rash) AND improvement in at least one symptom (eg skin, oral mucosal, ocular, or GI symptoms).boolean

Chunk 30

VEXAS syndrome

VEXAS syndrome — coverage questions

Concomitant therapy: Will the requested medication be given in combination with a biologic, targeted synthetic oral small molecule, conventional DMARD, or no combination?choice

List provided (chunk 31)

Current tocilizumab use: Is the patient currently receiving a tocilizumab product (subcutaneous or intravenous)?boolean

Chunk 31

Minimum duration for response assessment: Has the patient already received at least 6 months of therapy with a tocilizumab product? (Answer No if <6 months or restarting)boolean

Chunk 31

Ongoing response ≥6 months: When assessed by at least one objective measure, has the patient experienced a beneficial clinical response from baseline? (Examples: resolution of fever, improvement in skin manifestations, normalization of CRP/ESR, reduced corticosteroid dose) AND improvement in at least one symptom (eg decreased joint pain, decreased fatigue, decreased cough/dyspnea, improved ocular symptoms).boolean

Chunk 32

Genetic confirmation for new starts: For new starts or patients receiving <6 months: does the patient have a molecular genetic test demonstrating a pathogenic or likely pathogenic UBA1 gene variant?boolean

Required per form (chunk 32)

Corticosteroid trial or contraindication: For new starts or patients receiving <6 months: has the patient tried or is the patient taking a systemic corticosteroid, or are systemic corticosteroids contraindicated? Document trial or contraindication.boolean

Chunk 32

Prescriber specialty: Is the medication being prescribed by or in consultation with a rheumatologist, hematologist, dermatologist, immunologist, or specialist in autoinflammatory conditions?boolean

Required for new starts or <6 months (chunk 32)

Codes and Therapy Duration Thresholds

J-code (provider entered)mixed

J-code

Field for entering applicable J-code for administered tocilizumab product (J-code not specified in excerpt)

Diagnosis codes (provider entered)ICD-10

ICD-10

Field for entering diagnosis ICD-10 code corresponding to selected indication (specific codes not listed in excerpt)

DMARD trial duration — RA

Minimum DMARD trial for RA new starts>= 3 months on one conventional synthetic DMARD (eg, methotrexate, leflunomide, sulfasalazine, hydroxychloroquine)

Minimum biologic trial for RA new starts>= 3 months on one biologic prior to tocilizumab for new starts or <6 months exposure

Rheumatologist involvementMedication prescribed by or in consultation with a rheumatologist is required for RA new starts or <6 months

Tocilizumab trial duration for response assessment

Tocilizumab response assessment interval>= 6 months of tocilizumab therapy before assessing beneficial clinical response for many indications

Documentation for continuationWhen on therapy >=6 months, providers must document objective improvement by at least one validated measure and symptom improvement

Applies to adult Still's/SJIA and multiple other indicationsForm differentiates new starts/<6 months vs continuation (>=6 months) across indications such as RA, Still's, SJIA

Therapy duration thresholds — summary

Common response-assessment threshold>= 6 months of therapy for response assessment for many indications

GVHD IV minimum duration>= 1 month of IV tocilizumab therapy is required (minimum) before considering continuation/assessment

Restarting or <thresholdsAnswer 'No' for duration questions if patient has received less than the specified duration or is restarting therapy

Required Actions, Documentation, and Prior Authorization

Prior Authorization

Prior Authorization Required — Complete the Cigna Form

Prior authorization is required for Actemra/Avtozma/Tyenne. Use the Cigna prior authorization form and complete all required patient, prescriber, and medication fields (Cigna ID, date of birth, prescriber DEA/NPI/TIN, medication, dose, quantity, J‑code, ICD‑10, indication). Incomplete forms or missing required responses may result in denial.

Complete identifiers: Cigna ID, DOB, and prescriber DEA, NPI or TIN
Include medication, dose, quantity, J‑code, ICD‑10 diagnosis, and indication
Use Cigna prior authorization form (available via CoverMyMeds or SureScripts in the EHR)

Documentation Required

Prior Authorization Questionnaire Requirements

Providers must complete the indication‑specific prior authorization questionnaire items on the Cigna form. For each indication the form asks about specialist involvement, prior therapy trials and durations, current tocilizumab exposure and duration, concomitant medications, site of administration, and objective measures of response for continuation requests. Failure to answer indication‑specific questions may delay or deny coverage.

Indication selection is required (e.g., RA, SJIA, pJIA, VEXAS, GVHD, CRS, Castleman, GCA, Still's disease, etc.)
Questionnaire captures: specialist prescribing or consultation, prior systemic therapies tried, trial durations, and reason for intolerance/contraindication
For ongoing therapy, document objective measures (disease activity scores, labs, symptom improvement) per indication

Prior Authorization

Specialist Prescribing Requirement

When required by the indication, the medication must be prescribed by or in consultation with an appropriate specialist. Ensure the prescriber specialty and consultation documentation are included on the form.

Rheumatologist required for RA, Still's disease, SJIA, pJIA, and many autoinflammatory rheumatologic indications
Oncologist, hematologist, hepatologist, gastroenterologist, or pulmonologist required when indicated (for example CRS, GVHD, organ‑specific toxicities)
For VEXAS, prescriber should be a rheumatologist, hematologist, dermatologist, immunologist, or autoinflammatory specialist

Documentation Required

VEXAS Diagnostic and Prior Therapy Documentation

For VEXAS syndrome new starts or patients on therapy <6 months, documentation of a pathogenic or likely pathogenic UBA1 gene variant is required. Also document prior use of systemic corticosteroids (or contraindication) and specialist involvement.

Molecular genetic test showing pathogenic or likely pathogenic UBA1 variant required for new starts or <6 months on therapy
Document prior trial of systemic corticosteroids; if not tried, provide contraindication rationale
Prescriber should be or consult with an appropriate specialist (rheumatology, hematology, dermatology, immunology, or autoinflammatory specialist)

Documentation Required

Objective Response Documentation for Ongoing Therapy

For continuation (patients receiving therapy 6+ months or other applicable durations), provide objective documentation of clinical benefit from baseline using validated measures or clinical/laboratory improvements as specified per indication.

Rheumatoid arthritis: CDAI, DAS28‑ESR/CRP, RAPID‑3, SDAI, PAS‑II or similar
Juvenile arthritis and Still's disease: physician/parent global assessments, JADAS/cJADAS, JDAS, JSpADA, CRP/ESR, reduced steroid dose
GVHD/CRS/organ toxicities: organ‑specific labs (LFTs, blood counts), resolution of fever/rash, reduced steroid requirement
Document improvement in at least one symptom or functional measure compared with baseline

Step Therapy

RA Step Therapy and Specialist Involvement

Rheumatoid arthritis new starts (or patients receiving tocilizumab <6 months) must meet step therapy requirements: trial of at least one conventional synthetic DMARD for ≥3 months and assessment of prior biologic trials when applicable. The medication should be prescribed by or in consultation with a rheumatologist.

At least one conventional synthetic DMARD (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) trial for ≥3 months is required for RA new starts or <6 months tocilizumab exposure
Documentation of prior biologic trial(s) for ≥3 months may be required per form questions
Prescriber must be a rheumatologist or document rheumatology consultation

Step Therapy

Prior Systemic Therapy Required for New Starts

Many indications require prior systemic therapy trials before approval of tocilizumab IV for new starts, or documentation of intolerance/contraindication to those therapies. Provide dates, durations, and reasons for discontinuation when applicable.

pJIA/SJIA: trial of at least one other systemic therapy (e.g., methotrexate, leflunomide, sulfasalazine, NSAID, or a biologic) or documentation of contraindication
GVHD: trial of at least one systemic GVHD medication (for example corticosteroids, ruxolitinib) for new starts when applicable
CRS and immunotherapy‑related toxicities: documentation of symptomatic disease despite at least one systemic corticosteroid trial when indicated

OpenPayer

Tocilizumab (Actemra/Avtozma/Tyenne) prior authorization

Condition-Specific Coverage Criteria

Codes and Therapy Duration Thresholds

Required Actions, Documentation, and Prior Authorization

Clinical Background

Definitions and Examples

Policy Revision History